Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

805.20INR
18 Sep 2014
Price Change (% chg)

Rs12.90 (+1.63%)
Prev Close
Rs792.30
Open
Rs811.00
Day's High
Rs814.40
Day's Low
Rs800.50
Volume
266,335
Avg. Vol
166,526
52-wk High
Rs877.40
52-wk Low
Rs535.55

SUN.BO

Chart for SUN.BO

About

Sun Pharmaceutical Industries Limited is an international specialty pharma company. The Company manufactures and markets pharmaceutical formulations as branded generics, as well as generics in India, the United states and several other markets across the world. The Company’s business is divided into four segments: US Generics,... (more)

Overall

Beta: 0.62
Market Cap (Mil.): Rs1,641,190.00
Shares Outstanding (Mil.): 2,071.16
Dividend: 1.50
Yield (%): 0.19

Financials

  SUN.BO Industry Sector
P/E (TTM): 27.91 32.66 33.47
EPS (TTM): 28.39 -- --
ROI: -- 18.15 17.39
ROE: -- 18.86 18.25
Search Stocks

MARKET EYE -India's Sun Pharma gains; becomes first to license drug from innovator

* Sun Pharmaceutical Industries gains 2 percent. * Merck & Co Inc said it had licensed its experimental psoriasis drug to Sun. * First instance of an Indian company taking global rights for a novel drug, traders say. * Deal strengthens Sun's presence in the U.S. skin market, also boosts revenue potential, traders add. (abhishek.vishnoi@thomsonreuters.com / abhishek.vishnoi.thomsonreuters.com@reuters.net)

18 Sep 2014

Merck licenses experimental psoriasis drug to India's Sun Pharma

- Merck & Co Inc said it had licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd for $80 million.

17 Sep 2014

Sun's takeover of Ranbaxy may hurt competition - CCI

MUMBAI - India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.

04 Sep 2014

India regulator says Sun's takeover of Ranbaxy may hurt competition

MUMBAI - India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.

04 Sep 2014

India regulator says Sun's takeover of Ranbaxy may hurt competition

MUMBAI, Sept 4 - India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.

04 Sep 2014

Sun Pharma posts Q1 profit on strong U.S. sales

MUMBAI - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by market value, reported a better-than-expected first-quarter profit, reflecting higher sales in its largest market, the United States.

13 Aug 2014

Sun Pharma gains after earnings beat estimates

Reuters Market Eye - Sun Pharmaceutical Industries gains 1.6 percent after June-quarter earnings beat estimates on higher U.S. sales.

13 Aug 2014

MARKET EYE -India's Sun Pharma gains after earnings beat estimates

* Sun Pharmaceutical Industries gains 1.6 percent after June-quarter earnings beat estimates on higher U.S. sales. * Sequential rise of 20 percent in U.S. sales is a positive surprise, analysts say. (abhishek.vishnoi@thomsonreuters.com / abhishek.vishnoi.thomsonreuters.com@reuters.net)

13 Aug 2014

Ranbaxy posts loss on provision for U.S. settlement

MUMBAI - Generic drugmaker Ranbaxy Laboratories Ltd posted a net loss for the quarter to end-June after making a provision related to "ongoing settlement discussions" with U.S. government authorities.

29 Jul 2014

India's Ranbaxy Laboratories posts loss in June quarter

MUMBAI, July 29 - Indian drugmaker Ranbaxy Laboratories Ltd, which has agreed to be acquired by local rival Sun Pharmaceutical Industries Ltd, posted a net loss in the June quarter hit by a one-time provision.

29 Jul 2014

Earnings vs. Estimates

Search Stocks